West Pharma (WST) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Price: $394.03 +0.14%
EPS Growth %: +12.2%
Financial Fact:
Selling, general and administrative expenses: 58.3M
Today's EPS Names:
ORPB, PBCO, SICP, More
EPS Growth %: +12.2%
Financial Fact:
Selling, general and administrative expenses: 58.3M
Today's EPS Names:
ORPB, PBCO, SICP, More
Join SI Premium – FREE
West Pharma (NYSE: WST) reported Q4 EPS of $0.54, $0.02 worse than the analyst estimate of $0.56. Revenue for the quarter came in at $382.3 million versus the consensus estimate of $387.31 million.
For earnings history and earnings-related data on West Pharma (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- First Western Financial, Inc. (MYFW) Reports In-Line Q3 EPS
- National Bankshares Inc (NKSH) Misses Q3 EPS by 12c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
